April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
4 citations
,
August 2024 in “International Journal of Molecular Sciences” EBGS reduces platelet adhesion, potentially helping prevent blood clots.
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab in treating psoriasis.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
5 citations
,
February 1977 in “Archives of Dermatology” The study suggests that complement activation, not immunoglobulins, may be important in erythema nodosum leprosum.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
4 citations
,
July 2025 in “International Journal of Molecular Sciences” Targeting amphiregulin may improve treatment for fibrosis and cancer.
2 citations
,
June 2025 in “Preprints.org” Targeting amphiregulin may improve treatment for fibrotic diseases and cancer.
109 citations
,
February 2018 in “CB/Current biology” ERULUS controls root hair growth by regulating cell wall composition and pectin activity.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
76 citations
,
January 1998 in “Mammalian Genome” 17 citations
,
January 2015 in “Dermatology online journal” A patient's grey hair regained color during treatment with adalimumab.
75 citations
,
June 2005 in “Archives of Dermatology” Etanercept may not prevent alopecia areata from coming back.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
12 citations
,
April 2023 in “Molecular Pharmaceutics” A new patch can deliver stable antibodies over time for potential HIV treatment.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
July 2024 in “Journal of Investigative Dermatology” 5 citations
,
January 2018 in “Indian Journal of Dermatology/Indian journal of dermatology” A woman got a skin rash from taking aceclofenac, which went away after she stopped the drug.
January 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Certain genetic variants in ERN1, TACR3, and SPPL2C are linked to when Alzheimer's disease starts.
April 2020 in “Rheumatology” Rituximab therapy successfully treated a patient's complete body hair loss and was effective for six years.
53 citations
,
July 2009 in “Cancer Research” Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
29 citations
,
September 2018 in “Journal of the American Heart Association” EP 2 receptor is essential for heart repair by helping macrophages work properly.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
6 citations
,
September 2022 in “Frontiers in pharmacology” Epimedium extract helps increase skin pigmentation and could be a new treatment for conditions with reduced pigmentation.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
5 citations
,
November 2023 in “The Journal of Dermatology” Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.